Please assess the completion status of the following clinical trial:

Trial Title: PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women age 18 or older not greater than age 65 years~* Diagnosis of pulmonary arterial hypertension class 1, 3, 4, 5 (Dana Point 2008)~* NYHA (New York Health Association)/WHO (World Health Organization) Class I-III~* PAH medications must have been initiated according to the latest consensus statement recommendations and remained stable for the last 30 days~* Women of child-bearing age must use a double-barrier local contraception till completion of the study~* Subjects must demonstrate understanding of the study, sign the informed consent, and have a reliable method of communication for contact and ability to comply with the study requirements~Exclusion Criteria:~* Participation in any other treatment studies during enrollment~* Significant illness in the past 30 days requiring hospitalization~* Hepatic insufficiency (transaminase levels \> 4 fold the upper limit of normal or bilirubin \> 2 fold the upper limit of normal),~* History of HIV, Hepatitis B or C~* Serum creatinine \> 2.8 mg/dl~* Pregnancy, breast-feeding, or lack of safe contraception~* Acute decompensated heart failure within past 30 days~* Known allergy or intolerance to carvedilol or other β blockers~* Significant, persistent bradycardia (resting heart rate \< 50 bpm) or hypotension (systolic blood pressure \< 100 mmHg or mean blood pressure \< 70 mmHg) at the time of enrollment~* Second or third-degree AV (Atrial Ventricular) block without pacemaker~* Use of CYP2D6 isoenzyme inhibitors (such as quinidine, fluoxetine, paroxetine, propafenone) which increase drug levels and result in greater vasodilating effects and hypotension~* Use of hypotensive drugs that deplete catecholamines (such as reserpine and monoamine oxidase inhibitors) which may lead to greater signs of hypotension or bradycardia~* Other medical and psychosocial conditions as determined by principal investigator deemed unsuitable for enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open Label Carvedilol (Type: ACTIVE_COMPARATOR): Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).